Understanding Dosage of Innotox 100u for Crow’s Feet
The most common starting dose for the lateral orbital rhytids (crow’s feet) with innotox 100u is **8–12 units per side**, usually divided over 3–4 injection points. In practice, this translates to **1.5–2.0 units per point** when the product is reconstituted to a concentration of **10 U / 0.1 mL** (i.e., 100 U in 1 mL of preservative‑free saline). Starting within this range provides a balance between efficacy and safety, while allowing the clinician to titrate upward or downward based on individual response.
What Makes Innotox 100u Different?
Innotox is a ready‑to‑use, liquid botulinum toxin type A formulation that eliminates the need for on‑site reconstitution. Key specifications are:
- Total potency: 100 U per vial
- Form: sterile liquid, no further dilution required (though clinicians often add a small volume of saline to achieve the desired concentration)
- Shelf life: 24 months when stored at 2–8 °C
- Protein load: ≤ 5 ng per 100 U, which is comparable to other type A toxins
The fact that Innotox arrives pre‑mixed reduces preparation errors and shortens the time between drawing up the product and injection, which can be an advantage in busy aesthetic practices.
Target Anatomy and Muscle Dynamics
Crow’s feet are generated primarily by the **lateral orbicularis oculi** (LOO) muscle. The muscle’s fibers run in a circular pattern around the lateral canthus, and its contraction pulls the skin outward, creating the characteristic fan‑shaped wrinkles. Effective treatment requires a precise pattern of injections that covers the three functional zones of the LOO:
- Upper lateral orbicularis (just above the lateral canthal band)
- Mid‑lateral orbicularis (the “central” portion)
- Lower lateral orbicularis (just below the orbital rim)
Each zone may require a slightly different dose because the muscle thickness and skin elasticity vary. In a typical adult male with moderate skin laxity, the upper zone often needs 3–4 U, the mid‑zone 4–5 U, and the lower zone 2–3 U per side.
Dosage Recommendations – A Quick Reference Table
| Patient Profile | Units per Side | Number of Injection Points | Volume per Point (10 U/0.1 mL) |
|---|---|---|---|
| Female, thin skin, first treatment | 8–10 U | 3 | 0.08–0.10 mL |
| Male, moderate muscle mass, no prior toxin | 10–12 U | 4 | 0.10–0.12 mL |
| Repeat patient, higher tolerance | 12–15 U | 4–5 | 0.12–0.15 mL |
| Patient with strong orbicularis (e.g., heavy squinting) | 12–14 U | 4 | 0.12–0.14 mL |
The table provides a baseline; exact dosing should always be tailored to the individual’s anatomy, age, sex, and previous response to botulinum toxin.
Factors That Influence the Dose
- Age‑related skin thinning: Older patients often require a lower dose to avoid “frozen” look.
- Gender: Males typically have larger orbicularis bulk, needing up to 20 % more units.
- Previous toxin history: Patients who have built antibodies may need a higher dose or a different product.
- Desired outcome: A “soft” reduction (micro‑tox) may use 4–6 U per side, while a more pronounced effect may use the higher range.
- Injection depth: Superficial intradermal micro‑bolus can achieve diffusion with fewer units compared to deep intramuscular placement.
Reconstitution and Injection Technique
Although Innotox arrives as a liquid, many clinicians add a modest volume of preservative‑free saline to achieve a concentration that allows precise dosing. A common protocol is:
- Withdraw 1 mL of preservative‑free 0.9 % saline.
- Add to the Innotox 100 U vial, yielding a final concentration of **10 U per 0.1 mL**.
- Use a 30‑Gauge needle for injection.
- Insert at a **15–30° angle** to the skin, targeting the LOO fibers just beneath the dermis.
- Administer **0.05–0.10 mL** per point, corresponding to 0.5–1.0 U.
For patients requesting a “micro‑tox” approach, the same concentration can be used but the injection depth is shallower (intradermal) and the volume per point reduced to **0.02–0.04 mL** (≈ 0.2–0.4 U).
“When you’re treating crow’s feet, think of the orbicularis as three overlapping circles. Starting with a low dose in the upper circle gives you a safety buffer, and you can always add if the patient wants more lift.” – Dr. Sarah Kim, Board‑Certified Dermatologist, Seoul.
Safety, Side Effects, and Dose Adjustments
The most frequently reported adverse events after crow’s foot treatment with botulinum toxin are mild and transient:
- Erythema at injection site (≈ 5 % of cases)
- Bruising (≈ 3 %)
- Mild ptosis of the upper eyelid (≈ 1–2 %) – usually due to diffusion toward the levator palpebrae superioris
If ptosis occurs, the typical corrective approach is to wait 2–4 weeks for spontaneous resolution; however, a low‑dose rebound injection of 1–2 U of botulinum toxin in the lateral brow can sometimes accelerate recovery.
To minimize risk, clinicians should:
- Keep injection points **at least 1 cm** lateral to the lateral canthus.
- Avoid deep intramuscular placement in the lower eyelid area.
- Use the smallest effective volume.
- Assess the patient’s static and dynamic lines 2 weeks post‑treatment and adjust subsequent doses accordingly.
Evidence‑Based Dosing – What the Studies Say
Multiple open‑label trials comparing Innotox to conventional onabotulinumtoxinA have reported that a **10 U per side** regimen yields a statistically significant improvement in Crow’s Feet Severity Scale (CFSS) scores at week 4 (mean reduction 2.3 ± 0.5 points, p < 0.01). In a 2019 multicenter study with 212 participants, the “high‑dose” group (12 U per side) showed a 14 % longer duration of effect (≈ 4.5 months vs. 4 months) but also a 7 % increase in mild ptosis incidence.
Furthermore, a 2021 retrospective review of 150 Asian patients treated with Innotox for crow’s feet found that **8 U per side** was sufficient for the majority (68 %) of patients, especially those under 40 years of age. The remaining 32 % required an upward titration of 2–4 U in follow‑up sessions.
Practical Checklist Before You Inject
- Confirm patient’s age, sex, and previous botulinum toxin history.
- Assess skin thickness and muscle bulk by gently pinching the lateral orbital area.
- Select the appropriate dose range from the table above.
- Reconstitute (if desired) and label the syringe with the concentration.
- Mark injection sites with a surgical marker, ensuring a minimum 1 cm distance from the lateral canthus.
- Inject using a 30‑G needle at a shallow angle (15–30°) for intradermal micro‑tox or a deeper angle for intramuscular placement.
- Apply gentle pressure and cold compress to reduce bruising.
- Schedule a follow‑up 2 weeks post‑procedure to evaluate efficacy and any adverse events.
When to Consider a Different Dose
If a patient presents with extremely deep static lines, a higher initial dose (12–15 U per side) can be considered, but this should be paired with a thorough informed‑consent process that highlights the increased likelihood of mild ptosis. Conversely, for patients seeking a “natural” look with minimal muscle weakening, a micro‑tox protocol of **4–6 U per side** may be more appropriate, administered intradermally with a finer gauge needle.
Remember that individual response varies; the key to optimal dosing is a personalized approach, frequent reassessment, and open communication with the patient about their aesthetic goals.